Since GBM is hyper-vascular in nature, different drugs e.g. vatalanib, cediranib, sunitinib, etc. have been used against VEGF-VEGFR pathway to control abnormal angiogenesis in clinical trials [28-33]. This evidence concerns the gene KDR and glioblastoma.